Plasmodium

Displaying 1 - 3 of 3CSV
Siqueira-Neto, J. L., Wicht, K. J., Chibale, K., Burrows, J. N., Fidock, D. A., & Winzeler, E. A. (2023). Antimalarial drug discovery: progress and approaches. Nature Reviews Drug Discovery, 22(10), 807–826. https://doi.org/10.1038/s41573-023-00772-9
Publication Date
Deni, I., Stokes, B. H., Ward, K. E., Fairhurst, K. J., Pasaje, C. F. A., Yeo, T., Akbar, S., Park, H., Muir, R., Bick, D. S., Zhan, W., Zhang, H., Liu, Y. J., Ng, C. L., Kirkman, L. A., Almaliti, J., Gould, A. E., Duffey, M., O’Donoghue, A. J., … Fidock, D. A. (2023). Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome. Cell Chemical Biology, 30(5), 470-485.e6. https://doi.org/10.1016/j.chembiol.2023.03.002
Publication Date
Arendse, L. B., Murithi, J. M., Qahash, T., Pasaje, C. F. A., Godoy, L. C., Dey, S., Gibhard, L., Ghidelli-Disse, S., Drewes, G., Bantscheff, M., Lafuente-Monasterio, M. J., Fienberg, S., Wambua, L., Gachuhi, S., Coertzen, D., van der Watt, M., Reader, J., Aswat, A. S., Erlank, E., … Chibale, K. (2022). The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages. Science Translational Medicine, 14(667). https://doi.org/10.1126/scitranslmed.abo7219
Publication Date